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This papn introduces the current statns of melanoma treat­
ment with various biologic response modifiers (BRMs) in 
Japan, with an emphasis on the clinical results of Interferon 
therapies. The authors also refer briefly to the current situa­
tion of interleukin-2 (IL-2) and tumor necrosis factor (TNF) 
in Japan. 
Many BRMs have been used in treatment of melanoma, 
e.g., IFN, IL-2, TNFs, BCG, MY-1 (DNA extracted from 
BCG), WPG (CWs of Bifidobacterium infantis, ATCC 
15697), OK-432 (Picihanil, Streptococcus pyogenes prepa­
ration), hestatin, and forphenicinol. Some of these have COI11-
T his paper describes the current status _of melanoma treatment with biologic response modi hers (llRM) in Japan. The first application of HRM to the treatment of melanoma by this method was in 1971, using BCG. Since then, we have experimented with the usc of 
various BRMs, including llCG-CWS, MY -1 (denatured single­
stranded DNA extracted from BCG), OK-432 (Streptococcus pyo­
genes preparation), WPG (CWS of Bifidobacterium infantis, 
ATCC 15697), forphenicinol, bestatin, interferon (lX, /3, and y), 
interleukin-2, and TNF. The following sections describe the cur­
rent research and development status, the phase of clinical trials, and 
experimental studies and their results for the abov(,-mentioned 
BRMs. 
MATERIALS AND METHODS 
Interferon (IFN) Sixteen IFN preparations, including both natu­
ral and recomhinant lX, /3, and )' IFNs, have been or ar(' now b('ing 
Lll'veloped by 12 pharmaceutical companies in Japan. Of thes(', nat­
ural IFN-/J (Feron, Toray) was the first to und('rgo a clinical trial 
(1979). This was followed by two, six, and seven preparations, of /3, 
n, and ;' IFNs, respectively, of which In, 1/3 , and 5)1 preparations are 
now being tested in clinical patients (phase II study). The present 
d('scription focuses on those preparations for which clinical trials 
have already been completed (Table I). 
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pleted clinical trials, while others are still undergoing clinical 
testing. Among IFN -lX, p, and y, intralesional administration 
of natural IFN-p was found to be more effective than IFN-lX 
for metastatic skin melanoma, the survival time of patients 
heing prolonged by the administration ofIFN-p. IFN-y ap­
peared to have lower efficacy than IFN-lX and p. 
The frequency of BRM application to melanoma treat­
ment will increase. The authors foresee that combinations 
with radio- and/or other chemotherapy will be more com­
mon than the single use of a BRM, especially in the case of 
IFN.] illPest Damatol 92:3265-3285, 1989 
Interleukin-2 (IL-2) Recombinant IL-2 (rIL-2) is currently being 
tested for its clinical usefulness in two ongoing trials in Japan. Un­
fortunately. however, th(' recomm('n,kd dosage for this intnleukin 
varies gr('atly from 5,000 -50,000 units to 5 - 105 X 10 units/day, 
because the international unit has not been defined yet. 
In the current melanoma trials rIL-2 is being administered at the 
above-mentioned dosages either systemically (i.m. or i.v.), for more 
than four consecutive weeks, or intralesionally, daily or on alternate 
days. 
Tumor Necrosis Factor (TNF) Recombinant and natural TNFs 
W('fe administered i.m. to four cases of Stage IV malignant mela­
noma; two for each form of TNF. All four cases showed a signifi­
cant side elfe-ct, including fev('r, chillin('ss, and decreased blood 
pressure. Th liS, they are now being administer('d intralesionally to 
eight cases of Stage IV malignant melanoma with skin metastasis. 
RESULTS AND DISCUSSION 
Interferon (IFN) 
Nallna! IFN-/3: Natural IFN-/3 was the first interferon introduced 
into experimental and clinical tumor immunotherapy in Japan, and 
one preparation (Fe-ron, Toray) has been officially approved for 
therapeutic usc. A similar preparation developed by another manu­
facturer has also complct('d clinical testing. Natural IFN-/3 is ad­
ministered either i.v. or i.m. Systemic treatment is appropriate for 
both primary and metastatic lcsions of malignant melanoma [ 1  -3]. 
The dosage, as a rule, is 1-3 X 106 IU/day, given by i.v. drip 
infusion for four weeks. When used as preopcrative therapy for 
primary melanoma, the medication should be given for two weeks 
or more. In 13 melanoma patients, systemic therapy dicited PR 
(partial response; more than 50% r('duction in tumor size) in one 
and MR (minor response; 20%-50% reduction in tumor siz(') in 
one case each of lung metastasis and nodal metastasis. The observed 
side ('lfects w('re fever and anorexia, but none wer(' serious. 
Excellent results were obtained with intralesional administration 
of IFN-/3. The target lesions were cutaneous metastases of mela-
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Table I. Current Status of the Devclopment of IFNs 
Kinds and Number 
Type of Preparation Clinical Testing Completed 
Lymphoblastoid 3 
a Leukocyte 1 5 
Recombinant 2 
/J 
Fibroblast 2 2 Recombinant 
Leucocyte 1 2 ; ' Recombinant 6 
TOTAL 16 'I 
noma. The administered dose was 1 -3 X 106 IU, given daily or 
every other day, as a rule. The dosage was adjusted in consideration 
of the number ;md size of tumors, and response was evaluated after 
six or more doses were administered. Of 38 melanoma cases, 18 
(47.4%) showed a response ofPR or better (Table II). Generally, the 
antitumor response was rapid, and in many cases tumor regression 
became evident after administering three to six doses. 
Hne is an illustrative case of a 5 1-year-old male with a nodular 
melanoma of the toes who developed cutaneous metastases over the 
ipsilateral leg and thigh two years after amputation. After a 4-
month period of therapy with a total of 67 intralesional doses, 101 
injected lesions of the patient disappeared completely with no fur­
ther recurrence of metastasis. Now, five years after this IFN ther­
apy, the patient is healthy and free of malignant metastasis. 
Tumor tissues treated by intratumoral IFN-P administration were 
examined histopathologically and immunohistologically. Tumors 
resected 48 h after administering 6 X 105 IU of IFN-P showed nu­
merous aggregates of lymphocytes that gathered around tumor cells 
and disrupted their cellular architecture. They were Leu 2a+ (sup­
pressor/cytotoxic), Leu 3a+ (helper/inducer), and Leu 2a± (cyto­
toxic T cells) (Fig I, bnlllJll arrow) . Cytotoxic T (t'lIs were in close 
contact with the tumor cells. Under an electron microscope both 
tumor cells and lymphocytes were in close contact with each other, 
and the tumor cells showed a profound degenerative change (Fig 2). 
Side effects of intralesional administration of IFN-P included 
reddening of the skin at the injection site and pain at the time of 
injection. Fever was usually low grade. Side effects were less fre­
quent and less severe than those after systemic administration. 
Rf(omhilJallt IFN-P: Recombinant IFN-p was administered system­
ically or intralesionally at the same dosage and by the same method 
as for natural IFN-p. Of four melanoma cases receiving systemic 
administration, there was one MR (shrinkage in size of lymph nodes 
involved), while PR was recorded in two of nine cases treated by 
intralesional administration (Table III). Side effects were somewhat 
more severe than with natural IFN-p. Clinical trials arc now under­
way [4,5]. 
Natl/raIIFN-O'.: The doses for both systemic and intralesional ad­
ministration of natural IFN-O'. were essentially the same and compa­
rable to the dosages of IFN -po Of 13 cases receiving systemic admin­
istration, three showed MR. The efficacy of intralesional 
administration is being assessed in an ongoing trial. Preliminary 
results indicate that 20 of 46 evaluable cases were rated as exhibiting 
a rcsponse ofPR or better (Table III). Unfortunately, howevn, the 
Table II. Therapcutic Results of IFN-P (Intralesional) to 
Cutaneous Metastasis of Melanoma' 
Cases NC' 
38 8 10 6 (, 
I'D.! 
8 
� Response ratc: generally, drug ellen becomes manifest after 3 - 6 doses. Tumors of 
less til;lll 1 em diamerer aTC sllsceptihle. 
b CR: Complete response. 
, PH.: partial response. 
J MR: minor response. 
r NC: no ChJngl�. 
{PI): progressi�(" dise;1St'. 
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Figure 1. Leu 2a+ T cells (arroll» are seen in close contact with a tllmor cell 
after intratumoral inJCction of IFN-/J, 6 X 105 IU. Bar: 2.0 tiM. 
visible dfect initiated a little slower than that of IFN-P, and a 
smaller perccntage of cases showed CR (complcte response). A 
higher dosage and a longer term of administration secm neccssary. 
Sidc effccts were virtually the same as those ohserved with IFN-p. 
Immunohistopathologic and electron microscopic ohservations in­
dicated that while a small numhcr of T lymphocytes were found in 
tumor tissues after treatment, the cytotoxic action appeared some­
what less potent than that sccn after the usc of IFN-/l [4.5]. 
Rc(om[,inant IFN-O'. : The target disease' state, mcthod of adminis­
tration, and dosage werc virtu�lIy the same as for natural IFN-P and 
O'.. Two different types (IFN-O'.2b and O'.2a) devdoped by two manu­
facturers are availahle in Japan. In view of the failure of systemic 
administration to elicit a favorahle respoIlSe, intralesional il�ection 
was cmployed in 30 cases. The treatment was evaluated as effective 
in 13 cases (efficacy rate: 43.3%) (Tahlc III). Thc side effects wcte 
similar to thmc seen with thc aforementioned types of IFN. Histo­
pathologic and electron microscopic studie's suggested that recom­
binant IFN-a is equal to or somewhat less potent than natural 
IFN-/l in its activity in cliciting a cell-mediated immune rcspollSe 
[4,51· 
IFN-;': The intralesionally administere'd natural IFN-)' was effcc­
tive in three of eight cases (Table III). The overall results. however. 
Figure 2. Electron micrograph after 2 doses of IFN-fJ 6 X lOs IU. The 
tllmor cell (T) has ullLkrgonc pro nOli need dq�ellt'rative challges, and a Iym­
phocytc (L) which resemhles an NK cell is scell ill contact with the tllmor 
cell. A part of the membrallollS structures of the two cells is dissolvill�. Rar: 
1.0 pM. 
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Table III. Clinical EfFect of IFN Preparations on Cutaneous 
Metastasis of Melanoma (Intralesionally Administered) 
20/46" 
(43.5'0,) 
r1FN-a 
13/30 
(43.3%) 
IFN-fJ 
18/38 
(47.4%) 
J Currentlv hcing tested ill oll�()il1g nial>;;. 
f, i{esptHl\ivc c.l�c"'/l'vaillatcd cases. 
r1FN-fJ' 
2/'.1 
(22.2%) 
IFN-r 
3/8 
(37.5%) 
----
r1FN-)" 
13/42 
(3 101<,) 
appeared to he inferior to those of IFN-O' and fJ. The efficacy of 
systemic administration could not he assessed hecause of the limited 
numher of cases available [5,6]. 
RClwllhillall t IFN-)': A favorable response was e'licited from intrale­
sionally injected IFN-y in 13 of 42 cases (Table III). This type of 
IFN is still heing tested clinically in trials, and its therapeutic effec­
tiveness has been indicated in a study. While few melanoma cases 
responded favorahly to systematically administered rIFN-y, mycosis 
fungoides were susceptible to this regimen. Side effects were similar 
to those of 0', fJ IFNs [5,6]. 
Tissl/c ClIImltratioll 4 IFN Fol/owillg Illtra/csiolla/ Admillistration: 
IFN shows rclatively potent, antitumor activity when administered 
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Figure 3. Tumor tissue levels of IFN following intralcsional administra­
tion. r1FN-r is under deliberation because of being based on a limited num­
her of cases. 
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intratumor:dly. The' tissue levcls oflFN we're dctermined serially in 
tcrms of anti�iral activity after intralesional administration. 
. 
IFN-jJ reached the highest level of concentration in the tumor 
tissuc, i.e., 2 X 10' IU / g at 2 h and morerhan 2 X 103 IU / g at 24 h 
after a dose of 106 IU. Similar stud ie's on r IFN -O'A and r IFN -Y (Fig 
3) showed that high tumor tissuc levels, although lower than with 
IFN-jJ, were maintained over a long period of time. This feature 
may account partly for the antitumor efficacy of IFN. On the othcr 
hand, a significant enhancement of the cell-mcdiated immune' re­
sponse in the affected site may also be comidcred to be an important 
contrihutory factor. 
Interleukin-2 (IL-2) Preliminary results indicate that melanoma 
is not significantly susceptihle to systemic treatment of r IL-2, hur 
moderately responsive to intralesional injection. Adoptive immu­
notherapy with LAK (lymphokine-activated killer) cells has been 
undertaken. In Japan no attempt has yet been madc to usc LAK cells 
to treat melanoma. This ne'w therapcutic approach require'S further 
studies to eva I uate its effectiveness. 
Tumor Necrosis Factor (TNF) In Japan, TNF, both as a natural 
and recombinant preparation, is being tested in clinical trials, with 
phase II studies just starting. At the prcscnt time this agent in sys­
temic administration appears to be less promising, while intrale­
sional injcctions have shown efficacy in some cases. The only side 
effect documented so far is fcver, the severity of which is dose-de­
pendent. Thf administration method is the same as for IFN and 
I L-2. The rccommended dose is 5,000 to 50,000 units/day for natu­
ral TNF and to 5 X 105 units for recomhinant TNF. 
Other Biologic Response Modifiers (BRMs) Other BRMs 
currently undergoing clinical testing including BCG, MY - 1, 
WPG, OK-432, bfstatin, and forphenicinol. Description of these 
agents is omitted here. The frequency of BRM administration for 
the treatment of mclanoma will be quite high. BRMs may not be 
llScd alone, but in combination of or concomitant with radio- and/ 
or chemotherapy, or for the induction of effector cells. We expt'ri­
enced a combination of systemically administered IFN-fJ and other 
BRMs to he effective in the treatmfnt of pulmonary and brain 
metastases of melanoma. Future investigations on combination 
therapies will certainly find effective and efficient methods of use 
for BRMs. 
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